Skip to main content
. Author manuscript; available in PMC: 2024 Jan 1.
Published in final edited form as: J Geriatr Oncol. 2022 Sep 23;14(1):101377. doi: 10.1016/j.jgo.2022.09.006

Table 3.

Adverse events related to either chemotherapy in the triple-negative cohort (cohort 1) (n, %)

Toxicity Grade 2 Grade 3 Grade 4
Neutrophil count decreased 2(10) 9(45) 4(20)
White blood cell decreased 2(10) 3(15) --
Fatigue 10(50) 1(5) --
Peripheral sensory neuropathy 7(35) -- --
Anemia 3(15) 3(15) --
Alopecia 5(25) -- --
Diarrhea 2(10) 2(10) --
Infusion related reaction 4(20) -- --
Nausea 4(20) -- --
Dysgeusia 3(15) -- --
Hyponatremia 2(10) 1(5) --
Mucositis oral 3(15) -- --
Constipation 2(10) -- --
Creatinine increased 2(10) -- --
Generalized muscle weakness 1(5) 1(5) --
Platelet count decreased 2(10) -- --
Rash acneiform 1(5) 1(5) --
Urinary tract infection 2(10) -- --
Alanine aminotransferase increased 1(5) -- --
Anorexia 1(5) -- --
Arthralgia 1(5) -- --
Aspartate aminotransferase increased 1(5) -- --
Blood bilirubin increased 1(5) -- --
Blurred vision 1(5) -- --
Chills 1(5) -- --
Dehydration 1(5) -- --
Dry mouth 1(5) -- --
Dyspepsia 1(5) -- --
Dyspnea -- 1(5) --
Enterocolitis infectious -- 1(5) --
Fall 1(5) -- --
Febrile neutropenia -- 1(5) --
Gastroesophageal reflux disease 1(5) -- --
Gastrointestinal disorders - Other, specify 1(5) -- --
Insomnia 1(5) -- --
Myalgia 1(5) -- --
Paresthesia 1(5) -- --
Pruritus 1(5) -- --
Rash maculo-papular 1(5) -- --
Skin infection -- 1(5) --
Vaginal dryness 1(5) -- --
Vomiting 1(5) -- --
Weight loss 1(5) -- --